(AOF) – NFL Biosciences drops (-26.62% to 2.04 euros) even as it announces the positive results of the Precesto study aimed at better describing the effect of its product NFL-101, namely a “ clinically relevant reduction in smoking satisfaction among smokers. The biotech specialist in addiction treatment also announces that its management will propose during the Board of Directors meeting on October 5, 2023 to modify the strategy for communicating the results of Cesto II, expected in July 2024, by maintaining blindness throughout the duration of the study.
Precesto is an exploratory Phase 2a study, placebo-controlled, crossover over two periods of 28 days each, randomized, double-blind, including 34 smokers who do not wish to quit smoking and who have high satisfaction with smoking. NFL Biosciences emphasizes that the study “confirms the therapeutic potential” of NFL-101.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Biotechs put to the test
These companies are suffering from a much less favorable economic cycle, which is reflected in particular by a drop in venture capital financing of start-ups. These companies are therefore obliged to carry out layoff plans. Added to this is a much more restrictive regulatory framework. First, in the United States, measures linked to the Inflation Reduction Act (IRA) could have a strong impact on the margins of stakeholders. Indeed, from 2026, the federal Medicare program will be able to renegotiate the price of drugs marketed for nine years (chemical) or 13 years (biological), with discounts that could range from 35 to 60% for biotechs. Likewise, in Europe, with the new drug regulations presented in Brussels in April, the duration of patent protection will be reduced if the innovative treatment is not marketed in all member countries within two years.
2023-09-25 08:42:00
#NFL #Biosciences #positive #results #NFL101 #smoking
/origin-imgresizer.eurosport.com/2024/05/21/3972125-80637208-2560-1440.jpg?fit=300%2C300&ssl=1)